Literature DB >> 26892906

Electrode array-eluted dexamethasone protects against electrode insertion trauma induced hearing and hair cell losses, damage to neural elements, increases in impedance and fibrosis: A dose response study.

Esperanza Bas1, Jorge Bohorquez2, Stefania Goncalves1, Enrique Perez1, Christine T Dinh1, Carolyn Garnham3, Roland Hessler3, Adrien A Eshraghi1, Thomas R Van De Water4.   

Abstract

We evaluated the effects of dexamethasone base (DXMb) containing electrode arrays in a guinea pig model of cochlear implantation to determine if eluted DXMb could protect the cochlea against electrode insertion trauma (EIT)-induced: 1) loss of hair cells; 2) disruption of neural elements; 3) increases in hearing thresholds; 4) increased electrical impedance and 5) fibrosis. A guinea pig model of EIT-induced hearing and hair cell losses was used to test silicone electrode arrays that contained either 10%, 1%, 0.1%, or 0% levels of micronized DXMb. These four types of electrode arrays were implanted into the scala tympani via basal turn cochleostomies and left in place for 3 months. Hearing thresholds were determined by ABR and CAP recordings in response to a series of defined pure tone stimuli (i.e. 16-0.5 kHz). Changes in impedance were measured between the implant electrode and a reference electrode. Hair cell counts and neural element integrity were determined by confocal microscopy analyses of stained organ of Corti whole mounts obtained from 90 day post-implantation animals. Fibrosis was measured in Masson trichrome stained cross-sections through the organ of Corti. The results showed that either 10% or 1.0% DXMb eluting electrode arrays protected; hearing thresholds, hair cells, and neural elements against EIT-induced losses and damage. Electrode arrays with 0.1% DXMb only partial protected against EIT-induced hearing loss and damage to the cochlea. Protection of hearing thresholds and organ of Corti sensory elements by electrode-eluted DXMb was still apparent at 3 months post-EIT. All three concentrations of DXMb in the electrode arrays prevented EIT-induced increases in impedance. EIT-initiated fibrosis was significantly reduced within the implanted cochlea of the two DXMb concentrations tested. In conclusion, DXMb eluting electrodes protected the cochlea against long term increases in hearing thresholds, loss of hair cells, damage to neural elements and increases in impedance and fibrosis that result from EIT-initiated damage. The protection achieved by DXMb-eluting electrodes was dose dependent. Establishing a significant level of trauma induced elevation in hearing thresholds was important for the determination of the otoprotective effects of array-eluted DXMb.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cochlear implantation; Hair cell loss; Hearing loss; Increased impedance; Insertion trauma; Local delivery of dexamethasone; Otoprotection

Mesh:

Substances:

Year:  2016        PMID: 26892906     DOI: 10.1016/j.heares.2016.02.003

Source DB:  PubMed          Journal:  Hear Res        ISSN: 0378-5955            Impact factor:   3.208


  29 in total

1.  The pattern and degree of capsular fibrous sheaths surrounding cochlear electrode arrays.

Authors:  Reuven Ishai; Barbara S Herrmann; Joseph B Nadol; Alicia M Quesnel
Journal:  Hear Res       Date:  2017-02-17       Impact factor: 3.208

Review 2.  [Intracochlear drug delivery in combination with cochlear implants : Current aspects].

Authors:  S K Plontke; G Götze; T Rahne; A Liebau
Journal:  HNO       Date:  2016-11       Impact factor: 1.284

3.  Hearing Changes After Intratympanically Applied Steroids for Primary Therapy of Sudden Hearing Loss: A Meta-analysis Using Mathematical Simulations of Drug Delivery Protocols.

Authors:  Arne Liebau; Olivia Pogorzelski; Alec N Salt; Stefan K Plontke
Journal:  Otol Neurotol       Date:  2017-01       Impact factor: 2.311

4.  Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial.

Authors:  Farnaz Matin-Mann; Ziwen Gao; Jana Schwieger; Martin Ulbricht; Vanessa Domsta; Stefan Senekowitsch; Werner Weitschies; Anne Seidlitz; Katharina Doll; Meike Stiesch; Thomas Lenarz; Verena Scheper
Journal:  Pharmaceutics       Date:  2022-06-11       Impact factor: 6.525

Review 5.  Current Concepts and Future Trends in Increasing the Benefits of Cochlear Implantation: A Narrative Review.

Authors:  Cristina Maria Blebea; Laszlo Peter Ujvary; Violeta Necula; Maximilian George Dindelegan; Maria Perde-Schrepler; Mirela Cristina Stamate; Marcel Cosgarea; Alma Aurelia Maniu
Journal:  Medicina (Kaunas)       Date:  2022-05-31       Impact factor: 2.948

6.  A Xenograft Model of Vestibular Schwannoma and Hearing Loss.

Authors:  Christine T Dinh; Olena Bracho; Christine Mei; Esperanza Bas; Cristina Fernandez-Valle; Fred Telischi; Xue-Zhong Liu
Journal:  Otol Neurotol       Date:  2018-06       Impact factor: 2.311

7.  Delayed changes in auditory status in cochlear implant users with preserved acoustic hearing.

Authors:  Rachel A Scheperle; Viral D Tejani; Julia K Omtvedt; Carolyn J Brown; Paul J Abbas; Marlan R Hansen; Bruce J Gantz; Jacob J Oleson; Marie V Ozanne
Journal:  Hear Res       Date:  2017-04-12       Impact factor: 3.208

Review 8.  Electric and Acoustic Stimulation in Cochlear Implant Recipients with Hearing Preservation.

Authors:  Christopher Welch; Margaret T Dillon; Harold C Pillsbury
Journal:  Semin Hear       Date:  2018-10-26

9.  Metabolic reprogramming of inner ear cell line HEI-OC1 after dexamethasone application.

Authors:  Michel Kather; Sabine Koitzsch; Bernhard Breit; Stefan Plontke; Bernd Kammerer; Arne Liebau
Journal:  Metabolomics       Date:  2021-05-24       Impact factor: 4.290

Review 10.  Advances in hearing preservation in cochlear implant surgery.

Authors:  Osama Tarabichi; Megan Jensen; Marlan R Hansen
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2021-10-01       Impact factor: 1.814

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.